|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Japan Society of Gynecologic Oncology
(eds), . Formulation Committee of the Treatment Guidelines for
Cervical Cancer, 2011. Kanehara & Co.; Tokyo: 2011, (In
Japanese).
|
|
4
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology, . Cervical Cancer
Version II. 2013, https://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf
|
|
5
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: An update of
radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.PubMed/NCBI
|
|
8
|
Sala P, Bogliolo S, Barra F, Fazio A,
Maramai M, Cassani C, Gardella B, Babilonti L, Giannelli F,
Mammoliti S, et al: Neoadjuvant chemotherapy followed by radical
surgery versus concurrent chemo-radiotherapy in the treatment of
locally advanced cervical cancer: A multicenter retrospective
analysis. J Invest Surg. 8:1–7. 2020. View Article : Google Scholar
|
|
9
|
Souhami L, Gil RA, Allan SE, Canary PC,
Araújo CM, Pinto LH and Silveira TR: A randomized trial of
chemotherapy followed by pelvic radiation therapy in stage IIIB
carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A and Yen
MS: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical cancer study group of the Asian oceanian clinical oncology
association. J Clin Oncol. 13:444–451. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang F, Xing P, Song F, Du X, Wang G,
Chen K and Yang J: The role of T-box genes in the tumorigenesis and
progression of cancer. Oncol Lett. 12:4305–4311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papaioannou VE: The T-box gene family:
Emerging roles in development, stem cells and cancer. Development.
141:3819–3833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bilican B and Goding CR: Cell cycle
regulation of the T-box transcription factor tbx2. Exp Cell Res.
312:2358–2366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abrahams A, Parker MI and Prince S: The
T-box transcription factor Tbx2: Its role in development and
possible implication in cancer. IUBMB Life. 62:92–102.
2010.PubMed/NCBI
|
|
15
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-Box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vance KW, Carreira S, Brosch G and Goding
CR: Tbx2 is overexpressed and plays an important role in
maintaining proliferation and suppression of senescence in
melanomas. Cancer Res. 65:2260–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jacobs JJ, Keblusek P, Robanus-Maandag E,
Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ,
Koh EY, Daley GQ and van Lohuizen M: Senescence bypass screen
identifies TBX2, which represses Cdkn2a (p19(ARF) and is amplified
in a subset of human breast cancers. Nat Genet. 26:291–299. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Zhu LJ, Yang YC, Wang ZX and Wang
R: miR-224 promotes the chemoresistance of human lung
adenocarcinoma cells to cisplatin via regulating G1/S
transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer.
15:339–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taneja P, Maglic D, Kai F, Zhu S, Kendig
RD, Fry EA and Inoue K: Classical and novel prognostic markers for
breast cancer and their clinical significance. Clin Med Insights
Oncol. 4:15–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nandana S, Tripathi M, Duan P, Chu CY,
Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, et
al: Bone metastasis of prostate cancer can be therapeutically
targeted at the TBX2-WNT signaling axis. Cancer Res. 77:1331–1344.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z and Guo Y: High TBX2 expression
predicts poor prognosis in non-small cell lung cancer. Neoplasma.
61:476–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu H, Liu BO, Liu A, Li K and Zhao H:
T-box 2 expression predicts poor prognosis in gastric cancer. Oncol
Lett. 10:1689–1693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Y, Li Z, Zhong Q, Li G, Zhang Y and
Huang Z: Association of TBX2 and P21 expression with
clinicopathological features and survival of laryngeal squamous
cell carcinoma. Int J Clin Exp Med. 7:5394–5402. 2014.PubMed/NCBI
|
|
24
|
Mahlamäki EH, Bärlund M, Tanner M,
Gorunova L, Höglund M, Karhu R and Kallioniemi A: Frequent
amplification of 8q24, 11q, 17q and 20q-specific genes in
pancreatic cancer. Genes Chromosomes Cancer. 35:353–358. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davis E, Teng H, Bilican B, Parker MI, Liu
B, Carriera S, Goding CR and Prince S: Ectopic Tbx2 expression
results in polyploidy and cisplatin resistance. Oncogene.
27:976–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ismail A and Bateman A: Expression of TBX2
promotes anchorage-independent growth and survival in the
p53-negative SW13 adrenocortical carcinoma. Cancer Lett.
278:230–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wansleben S, Davis E, Peres J and Prince
S: A novel role for the anti-senescence factor TBX2 in DNA repair
and cisplatin resistance. Cell Death Dis. 4:e8462013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuji K, Yamada R, Kawabata M, Mitsuzane
K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon
occluded arterial infusion of anticancer drugs on the prognosis of
cervical cancer treated with radiation therapy. Int J Radiat Oncol
Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen B, Wang L, Ren C, Shen H, Ding W, Zhu
D, Mao L and Wang H: The effect of neoadjuvant chemotherapy on
lymph node metastasis of FIGO stage IB1-IIB cervical cancer: A
systematic review and meta-analysis. Front Oncol. 10:5702582020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Vincenzo R, Ricci C, Fanfani F, Gui B,
Gallotta V, Fagotti A, Ferrandina G and Scambia G: Neoadjuvant
chemotherapy followed by conization in stage IB2-IIA1 cervical
cancer larger than 2 cm: A pilot study. Fertil Steril. 115:148–156.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Z, Huang B, Liu C, Yang Y, Rao Y, Du Y
and Ma Y: Comparison of neoadjuvant treatments followed by radical
surgery or chemoradiation on quality of life in patients with stage
IB2-IIA cervical cancer. Gynecol Oncol. 157:536–541. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Panici PB, Bellati F, Manci N, Pernice M,
Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and Angioli R:
Neoadjuvant chemotherapy followed by radical surgery in patients
affected by FIGO stage IVA cervical cancer. Ann Surg Oncol.
14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bose RN: Biomolecular targets for platinum
antitumor drugs. Mini Rev Med Chem. 2:103–111. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brabec V and Kasparkova J: Molecular
aspects of resistance to antitumor platinum drugs. Drug Resist
Updat. 5:147–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morimoto A, Serada S, Enomoto T, Kim A,
Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M,
et al: Annexin A4 induces platinum resistance in a chloride-and
calcium-dependent manner. Oncotarget. 5:7776–7787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Surowiak P, Materna V, Kaplenko I,
Spaczyński M, Dietel M, Lage H and Zabel M: Augmented expression of
metallothionein and glutathione S-transferase pi as unfavourable
prognostic factors in cisplatin-treated ovarian cancer patients.
Virchows Arch. 447:626–633. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu
X, Yang Y, Mo W, Huang W, Khoo SK, et al: Role of eIF3a in
regulating cisplatin sensitivity and in translational control of
nucleotide excision repair of nasopharyngeal carcinoma. Oncogene.
30:4814–4823. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Q, Shi S, He W, Padilla MT, Zhang L,
Wang X, Zhang B and Lin Y: Retaining MKP1 expression and
attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance
through miR-940 inhibition. Oncotarget. 5:1304–1314. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu RY, Dong Z, Liu J, Zhou L, Huang W,
Khoo SK, Zhang Z, Petillo D, Teh BT, Qian CN and Zhang JT:
Overexpression of asparagine synthetase and matrix
metalloproteinase 19 confers cisplatin sensitivity in
nasopharyngeal carcinoma cells. Mol Cancer Ther. 12:2157–2166.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fujiwara K, Daido S, Yamamoto A, Kobayashi
R, Yokoyama T, Aoki H, Iwado E, Shinojima N, Kondo Y and Kondo S:
Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1
in apoptosis and autophagy. J Biol Chem. 283:388–397. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya
R and Li LC: Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene
activation in human bladder cancer cells. Mol Cancer Ther.
7:698–703. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu ZM, Dai C, Huang Y, Zheng CF, Dong QZ,
Wang G, Li XW, Zhang XF, Li B and Chen G: Anti-cancer effects of
p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human
hepatocellular carcinoma cell lines. Acta Pharmacol Sin.
32:939–946. 2011. View Article : Google Scholar : PubMed/NCBI
|
